Phaseline

Targets › ATXN2

ATXN2 (Ataxin-2): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Neurology; next expected readout Dec 2026.

Involved in EGFR trafficking, acting as negative regulator of endocytic EGFR internalization at the plasma membrane. (UniProt, Q99700)

Open in Phaseline: the race on ATXN2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BiogenDiranersen
Antisense oligonucleotide targeting ATXN2 mRNA
ATXN2Phase 2Mild Cognitive Impairment Due to Alzheimer's DiseaseJun 2028
Arrowhead PharmaceuticalsARO-ATXN2 Injection
Antisense oligonucleotide targeting ATXN2 mRNA
ATXN2Phase 1Spinocerebellar Ataxia Type 2Dec 2026

Conditions

Spinocerebellar Ataxia Type 2 (1) Mild Cognitive Impairment Due to Alzheimer's Disease (1)

Modalities

small molecule (1), other (1)

Companies

Arrowhead Pharmaceuticals (1) Biogen (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.